Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AB-SA01: Phase I data

    AmpliPhi Biosciences Corp. (NYSE-M:APHB), Richmond, Va. Product: AB-SA01 (formerly AmpliPhage-002) Business: Infectious Molecular target: NA Description: Cocktail comprising 3 bacteriophages against Staphylococcus …

    Published on 9/26/2016
  • Amantadine: Phase III data

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS), Emeryville, Calif. Product: Amantadine (ADS-5102) Business: Neurology Molecular target: NA Description: Oral extended-release formulation of amantadine Indication: Treat …

    Published on 9/26/2016
  • AST-OPC1: Additional Phase I/IIa data

    Asterias Biotherapeutics Inc. (NYSE-M:AST), Menlo Park, Calif. Product: AST-OPC1 Business: Neurology Molecular target: NA Description: Human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells Indication…

    Published on 9/26/2016
  • BNC210: Phase II data

    Bionomics Ltd. (ASX:BNO; OTCQX:BNOEF), Thebarton, Australia Product: BNC210 Business: Neurology Molecular target: Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Description: Negative allosteric modulator of nicotinic…

    Published on 9/26/2016
  • Bydureon: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bydureon (Exenatide once weekly) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Description: Long-acting …

    Published on 9/26/2016
  • Cytomegalovirus: Phase II data

    Vical Inc. (NASDAQ:VICL), San Diego, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Cytomegalovirus (CMV) vaccine (VCL-CB01, ASP0113) (formerly TransVax) Business: Infectious Molecular target: Human …

    Published on 9/26/2016
  • Dasotraline: Phase II/III data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Dasotraline (SEP-225289) Business: Neurology Molecular target: Dopamine receptor; Norepinephrine transporter Description: Dopamine and …

    Published on 9/26/2016
  • Deutetrabenazine: Phase III data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Deutetrabenazine (Austedo) (SD-809) Business: Neurology Molecular target: Vesicular monoamine transporter 2 (VMAT2) (SLC18A2) Description: …

    Published on 9/26/2016
  • Ertugliflozin: Phase III data

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Ertugliflozin (MK-8835, PF-4971729, PF-04971729) Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter…

    Published on 9/26/2016
  • ETX0914: Phase II data

    Entasis Therapeutics Inc., Waltham, Mass. Product: ETX0914 (formerly AZD0914) Business: Infectious Molecular target: DNA gyrase; Topoisomerase IV Description: Benzisoxazole DNA gyrase and topoisomerase IV inhibitor …

    Published on 9/26/2016
  • Farxiga: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Farxiga ( Forxiga) dapagliflozin Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter 2 (SGLT2) Description: Sodium-glucose …

    Published on 9/26/2016
  • GS-5745: Phase II/III discontinued

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: GS-5745 Business: Autoimmune Molecular target: Matrix metalloproteinase 9 (MMP9) Description: Matrix metalloproteinase 9 (MMP9) mAb inhibitor Indication: …

    Published on 9/26/2016
  • GX-H9: Interim Phase II data

    Genexine Inc. (KOSDAQ:095700), Seoul, South Korea Handok Inc. (KSE:002390), Seoul, South Korea Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), Tianjin, China Product: GX-H9 Business: Endocrine/Metabolic Molecular …

    Published on 9/26/2016
  • GX-H9: Phase I data

    Genexine Inc. (KOSDAQ:095700), Seoul, South Korea Handok Inc. (KSE:002390), Seoul, South Korea Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), Tianjin, China Product: GX-H9 Business: Endocrine/Metabolic Molecular …

    Published on 9/26/2016
  • GX-H9: Phase II data

    Genexine Inc. (KOSDAQ:095700), Seoul, South Korea Handok Inc. (KSE:002390), Seoul, South Korea Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), Tianjin, China Product: GX-H9 Business: Endocrine/Metabolic Molecular …

    Published on 9/26/2016
  • Idalopirdine: Phase III data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Idalopirdine (Lu AE58054) Business: Neurology Molecular target: Serotonin (5-HT6) receptor Description: Selective …

    Published on 9/26/2016
  • Opicinumab: Additional Phase II data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Product: Opicinumab (Anti-LINGO-1) (BIIB033) Business: Autoimmune Molecular target: Leucine-rich repeat neuronal protein 1 (LINGO-1) Description: Antibody against leucine-rich…

    Published on 9/26/2016
  • Oral lasmiditan: Additional Phase III data

    CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD), Durham, N.C. Product: Oral lasmiditan (Oral COL-144) Business: Neurology Molecular target: Serotonin (5-HT1F) receptor Description: Selective agonist of serotonin (5-HT1F) …

    Published on 9/26/2016
  • Oral lasmiditan: Interim Phase III data

    CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD), Durham, N.C. Product: Oral lasmiditan (Oral COL-144) Business: Neurology Molecular target: Serotonin (5-HT1F) receptor Description: Selective agonist of serotonin (5-HT1F) …

    Published on 9/26/2016
  • Otiprio ciprofloxacin otic suspension: Phase IIIb data

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: Otiprio ciprofloxacin otic suspension (formerly OTO-201) Business: Infectious Molecular target: DNA gyrase Description: Sustained-release gel formulation of …

    Published on 9/26/2016
  • Pridopidine: Phase II data

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Pridopidine (Huntexil) (formerly ACR16) Business: Neurology Molecular target: Sigma-1 receptor Description: Small molecule sigma-1 receptor …

    Published on 9/26/2016
  • Proellex telapristone: Phase II data

    Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Proellex telapristone (CDB-4124) Business: Genitourinary Molecular target: Progesterone receptor (PGR) Description: Oral selective progesterone …

    Published on 9/26/2016
  • RSV F vaccine: Phase III data

    Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: RSV F vaccine Business: Infectious Molecular target: RSV F protein Description: Respiratory syncytial virus (RSV) vaccine targeting RSV viral fusion F protein …

    Published on 9/26/2016
  • Siponimod: Additional Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Siponimod (BAF312) Business: Autoimmune Molecular target: Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1) Description: Second-generation sphingosine…

    Published on 9/26/2016
  • SRX246: Phase II data

    Azevan Pharmaceuticals Inc., Bethlehem, Pa. Product: SRX246 Business: Neurology Molecular target: Vasopressin 1a (V1a) receptor Description: Arginine vasopressin 1a (V1a) receptor antagonist Indication: Treat …

    Published on 9/26/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993